Paraplatin Side Effects
Generic Name: carboplatin
Note: This page contains side effects data for the generic drug carboplatin. It is possible that some of the dosage forms included below may not apply to the brand name Paraplatin.
For the Consumer
Applies to carboplatin: intravenous powder for solution, intravenous solution
As well as its needed effects, carboplatin (the active ingredient contained in Paraplatin) may cause unwanted side effects that require medical attention.
Also, because of the way these medicines act on the body, there is a chance that they might cause other unwanted effects that may not occur until months or years after the medicine is used. These delayed effects may include certain types of cancer, such as leukemia. Discuss these possible effects with your doctor.
If any of the following side effects occur while taking carboplatin, check with your doctor or nurse as soon as possible:More common
- Pain at place of injection
- Black, tarry stools
- blood in urine or stools
- cough or hoarseness, accompanied by fever or chills
- fever or chills
- lower back or side pain, accompanied by fever or chills
- numbness or tingling in fingers or toes
- painful or difficult urination, accompanied by fever or chills
- pinpoint red spots on skin
- skin rash or itching
- unusual bleeding or bruising
- unusual tiredness or weakness
- Blurred vision
- ringing in ears
- sores in mouth and on lips
Some carboplatin side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:More common
- Nausea and vomiting
- unusual tiredness or weakness
- Constipation or diarrhea
- loss of appetite
This medicine may cause a temporary loss of hair in some people. After treatment with carboplatin has ended, normal hair growth should return.
For Healthcare Professionals
Applies to carboplatin: intravenous powder for injection, intravenous solution
Hematologic side effects have been reported to include thrombocytopenia with platelet counts below 50,000/mm3 in 25% of patients and in 35% of previously treated ovarian cancer patients (PTOCP), neutropenia with granulocyte counts below 1,000/mm3 in 16% of patients (21% of PTOCP), and leukopenia with WBC counts below 2,000/mm3 in 15% of patients (26% of PTOCP).[Ref]
Bone marrow suppression is the dose limiting toxicity of carboplatin. Marrow suppression is usually more severe in patients with impaired kidney function. Anemia with a hemoglobin count less than 11 g/dL has been observed in 71% of patients who started therapy with a baseline above that value. The incidence of anemia increases with increasing exposure. Bone marrow depression may be more severe when carboplatin is combined with other bone marrow suppressing drugs or with radiotherapy. One study has suggested that myelotoxicity could be minimized by the use of regimes based on the circadian rhythm of the bone marrow.[Ref]
Patients previously treated with emetogenic agents (especially cisplatin) have been more prone to vomiting. Nausea alone occurs in an additional 10% to 15% of patients. Prolonged administration of carboplatin (the active ingredient contained in Paraplatin) (either by continuous 24 hour infusion or daily pulse doses given for 5 consecutive days) was associated with less severe vomiting than the single dose intermittent schedule.[Ref]
Gastrointestinal side effects have included vomiting which occurred in 65% of patients and in 81% of PTOCP. In approximately one third of these patients, the vomiting was reported as severe. Other gastrointestinal side effects have included pain (17%), diarrhea (6%), constipation (6%), and stomatitis.[Ref]
Nervous system side effects have included peripheral neuropathies which have been reported in 4% of patients and 6% of PTOCP, with mild paresthesias occurring most frequently. Patients older than 65 years of age or previously treated with cisplatin have a been reported to have a 10% risk for peripheral neuropathies. Prolonged treatment, particularly in cisplatin-pretreated patients, may result in cumulative neurotoxicity.[Ref]
Hepatic side effects have included abnormal liver function tests reported in patients with normal baseline values receiving standard dosages including total bilirubin (5%), SGOT (15%), and alkaline phosphatase (24%), and 5%, 19%, and 37% respectively in PTOCP. These abnormalities were mild and reversible in about one-half of the cases.
In patients receiving very high dosages of carboplatin (the active ingredient contained in Paraplatin) and autologous bone marrow transplantation, severe abnormalities of liver function tests have been reported.[Ref]
Renal side effects have included abnormalities in 6% of serum creatinine test results (10% for PTOCP) and 14% of blood urea nitrogen test results (22% for PTOCP). Most of these reported abnormalities have been mild and about one-half of them were reversible. There have been at least two case reports in the literature of patients with preexisting renal dysfunction deteriorating into renal failure due to intravenous carboplatin (the active ingredient contained in Paraplatin) therapy. In one of the cases, renal failure followed high-dose therapy. In the other patient, acute renal failure was reversible. There have also been at least two reports in the literature of acute renal failure associated with the use of intraperitoneal carboplatin. Neither patient had a full return of renal function to baseline.[Ref]
Creatinine clearance is the most sensitive measure of renal function in patients receiving carboplatin. Creatinine clearance also appears to be the most useful test for correlating drug clearance and bone marrow suppression.[Ref]
Other side effects have included abnormally decreased serum electrolyte values such as sodium (29%), magnesium (29%), calcium (22%), and potassium (20%), 47%, 43%, 31%, and 28% respectively in PTOCP. Electrolyte abnormalities were rarely associated with symptoms.
Ototoxicity has been reported with the use of high-dose carboplatin (the active ingredient contained in Paraplatin)
The most frequently reported miscellaneous side effects were pain and asthenia.[Ref]
One study has noted that approximately 40 instances of hypersensitivity have been reported. The study further notes that there is generally a slow development of hypersensitivity, with reactions evolving only after several cycles of therapy.
Allergic reactions have generally been manageable with standard epinephrine, corticosteroid, and antihistamine therapy.[Ref]
Hypersensitivity side effects have been reported to include rash, urticaria, erythema, pruritus, and rarely bronchospasm and hypotension. Hypersensitivity reactions may be common in patients with gynecological malignancies.[Ref]
Metabolic side effects have included dehydration.
Ocular side effects including a case of blindness associated with the use of high dose carboplatin (the active ingredient contained in Paraplatin) have been reported.[Ref]
1. "Multum Information Services, Inc. Expert Review Panel"
2. "Product Information. Paraplatin (carboplatin)." Bristol-Myers Squibb, Princeton, NJ.
3. Kerr DJ, Lewis C, O'Neill B, et al "The myelotoxicity of carboplatin is influenced by the time of its administration." Hematol Oncol 8 (1990): 59-63
4. McDonald BR, Kirmani S, Vasquez M, Mehta R "Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature." Am J Med 90 (1991): 386-91
5. Deray G, Ben-Othman T, Brillet G, Baumelou B, Gabarre J, Baumelou A, Binet JL, Jacobs C "Carboplatin-induced acute renal failure." Am J Nephrol 10 (1990): 431-2
6. Mulder PO, Sleijfer DT, de Vries EG, Uges DR, Mulder NH "Renal dysfunction following high-dose carboplatin treatment." J Cancer Res Clin Oncol 114 (1988): 212-4
7. Chevreau C, Thomas F, Couteau C, Dalenc F, Mourey L, Chatelut E "Ototoxicity of high-dose Carboplatin." J Clin Oncol 23 (2005): 3649-50
8. Windom HH, McGuire WP, Hamilton RG, Adkinson NF "Anaphylaxis to carboplatin: a new platinum chemotherapeutic agent." J Allergy Clin Immunol Oct (1992): 681-3
9. Planner RS, Weerasiri T, Timmins D, Grant P "Hypersensitivity reactions to carboplatin." J Natl Cancer Inst 83 (1991): 1763-4
10. Sood AK, Gelder MS, Huang SW, Morgan LS "Anaphylaxis to carboplatin following multiple previous uncomplicated courses." Gynecol Oncol 57 (1995): 131-2
11. Broome CB, Schiff RI, Friedman HS "Successful desentization to carboplatin in patients with systemic hypersensitivity reactions." Med Pediatr Oncol 26 (1996): 105-10
12. Tonkin KS, Rubin P, Levin L "Carboplatin hypersensitivity: case reports and review of the literature." Eur J Cancer 29a (1993): 1356-7
13. Weidmann B, Mulleneisen N, Bojko P, Niederle N "Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management." Cancer 73 (1994): 2218-22
14. O'Brien MER, Tonge K, Blake P, et al "Blindness associated with high-dose carboplatin." Lancet 339 (1991): 558
It is possible that some side effects of Paraplatin may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
More about Paraplatin (carboplatin)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.